• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email
    SC 13G/A 1 tv01247-jazzpharmaceuticalsp.htm SCHEDULE 13G/A jazzpharmaceuticalsplc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Jazz Pharmaceuticals PLC

    Title of Class of Securities:  Common Stock

    CUSIP Number:  G50871105

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  G50871105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    54,434

    7.  SOLE DISPOSITIVE POWER

    6,211,844

    8.  SHARED DISPOSITIVE POWER

    151,904

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,363,748

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.11%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Jazz Pharmaceuticals PLC

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    Waterloo Exchange, Waterloo Road, 5th Floor
    Dublin 4

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    G50871105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $JAZZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    1/3/2024$160.00Outperform
    Robert W. Baird
    11/27/2023$170.00 → $135.00Buy → Neutral
    UBS
    9/29/2023Mkt Perform
    Raymond James
    More analyst ratings

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

      For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

      8/12/21 4:25:43 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

      DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST. An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days. About Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharma company whose purpose is to innovate to transfor

      4/30/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

      DUBLIN, April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who f

      4/25/25 11:27:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

      Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii) highlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients Jazz to host investor webcast on Tuesday

      4/23/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jazz Pharma upgraded by UBS with a new price target

      UBS upgraded Jazz Pharma from Neutral to Buy and set a new price target of $179.00 from $145.00 previously

      3/7/25 8:10:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Jazz Pharma from Overweight to Neutral

      2/26/25 1:51:25 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharma upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Jazz Pharma from Equal Weight to Overweight and set a new price target of $170.00 from $130.00 previously

      2/13/25 8:08:59 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/13/24 5:07:58 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      9/11/23 1:33:44 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

      SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

      2/9/23 11:25:15 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Cozadd Bruce C sold $176,350 worth of Ordinary Shares (1,500 units at $117.57), decreasing direct ownership by 0.34% to 438,807 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      5/5/25 7:00:39 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman & CEO Cozadd Bruce C sold $185,625 worth of Ordinary Shares (1,500 units at $123.75), decreasing direct ownership by 0.34% to 440,307 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      4/3/25 5:32:10 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Global Head of R&D & CMO Iannone Robert sold $332,605 worth of Ordinary Shares (2,403 units at $138.41), decreasing direct ownership by 3% to 79,621 units (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/12/25 2:24:35 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    See more
    • Jazz Pharmaceuticals Announces CEO Succession Plan

      Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board wil

      12/16/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

      Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-

      7/25/24 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer

      NodThera INC ("NodThera" or the "Company") NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership experience, including as President and COO of Jazz Pharmaceuticals and CEO of Sunesis PharmaceuticalsInterim CEO Alan Watt becomes President and CSO including leadership of R&D to further build out NodThera's pioneering work in CNS modulation of chronic inflammatory diseases BOSTON, MA, May 28, 2024 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the a

      5/28/24 7:00:00 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

      4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

      3/5/24 7:28:40 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    See more
    • Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

      DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2025 first quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at

      4/22/25 4:15:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Completes Acquisition of Chimerix

      - Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. "Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs," said Bruce Cozadd, chairman and chief executive officer of Jazz. "Dordaviprone has the potential to become the first an

      4/21/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

      – Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav® and Epidiolex® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total r

      2/25/25 4:05:00 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JAZZ
    SEC Filings

    See more
    • SEC Form 10-Q filed by Jazz Pharmaceuticals plc

      10-Q - Jazz Pharmaceuticals plc (0001232524) (Filer)

      5/7/25 7:33:48 AM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

      5/6/25 4:08:30 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Jazz Pharmaceuticals plc

      144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

      5/1/25 4:09:24 PM ET
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care